Table 2 .

Associations of MTR and MTHFR genotypes and gene promoter methylation: ORs (95% confidence intervals) for comparisons of controls to cases with promoter methylation (M), to cases without methylation (UM), and case-case comparisons cases

	MTR A2756G (rs1805087)			MTHFR A1298C (rs1801131)			MTHFR C677T (rs1801133)
	AA	AG	GG	AA	AC	CC	CC	CT	TT
Premenopausal
E-cadherin
M/ U/ control	30/121/370	15/44/161	3/6/31	19/73/257	15/53/233	4/18/49	22/73/227	15/68/251	5/21/68
M versus controls1	1.0	1.22 (0.64–2.31)	1.22 (0.35–4.21)	1.0	0.71 (0.37–1.35)	0.89 (0.30–2.64)	1.0	0.59 (0.31–1.13)	0.71 (0.26–1.90)
U versus controls1	1.0	0.83 (0.57–1.23)	0.57 (0.23–1.40)	1.0	0.67 (0.46–0.97)	1.07 (0.60–1.92)	1.0	0.82 (0.58–1.18)	0.92 (0.53–1.59)
M versus U2	1.0	1.49 (0.74–3.02)	2.24 (0.51–9.88)	1.0	1.05 (0.52–2.12)	0.62 (0.17–2.26)	1.0	0.73 (0.36–1.48)	0.78 (0.27–2.29)
p16
M/ U/ control	42/109/370	44/15/161	1/8/31	27/65/257	19/49/233	5/17/49	24/71/227	24/59/251	8/18/68
M versus controls1	1.0	0.87 (0.47–1.60)	0.28 (0.04–2.13)	1.0	0.77 (0.43–1.38)	0.95 (0.36–2.56)	1.0	1.01 (0.57–1.79)	1.21 (0.52–2.79)
U versus controls1	1.0	0.92 (0.62–1.36)	0.84 (0.38–1.88)	1.0	0.65 (0.44–0.94)	1.06 (0.58–1.92)	1.0	0.70 (0.49–1.01)	0.77 (0.44–1.37)
M versus U2	1.0	0.93 (0.47–1.83)	0.31 (0.04–2.61)	1.0	1.16 (0.61–2.24)	0.96 (0.32–2.84)	1.0	1.45 (0.76–2.78)	1.55 (0.60–4.00)
RAR-β2
M/ U/ control	37/114/370	22/37/161	1/8/31	25/67/257	16/52/233	6/16/49	25/70/227	25/58/251	5/21/68
M versus controls1	1.0	1.39 (0.80–2.42)	0.33 (0.04–2.49)	1.0	0.52 (0.28–0.95)	0.91 (0.36–2.25)	1.0	0.81 (0.47–1.41)	0.58 (0.22–1.55)
U versus controls1	1.0	0.75 (0.50–1.13)	0.80 (0.36–1.80)	1.0	0.74 (0.51–1.09)	1.09 (0.59–2.00)	1.0	0.75 (0.52–1.09)	0.99 (0.57–1.71)
M versus U2	1.0	1.86 (0.97–3.55)	0.45 (0.05–3.92)	1.0	0.76 (0.39–1.50)	0.96 (0.34–2.69)	1.0	1.04 (0.55–1.94)	0.56 (0.19–1.63)
Postmenopausal
E-cadherin
M/ U/ control	69/271/847	32/135/458	3/26/62	41/176/607	48/171/546	7/37/139	42/187/586	42/180/565	16/47/155
M versus controls1	1.0	0.91 (0.59–1.39)	0.66 (0.23–2.15)	1.0	1.24 (0.83–1.86)	0.72 (0.32–1.62)	1.0	1.07 (0.70–1.63)	1.46 (0.81–2.63)
U versus controls1	1.0	1.00 (0.79–1.26)	1.47 (0.91–2.38)	1.0	0.99 (0.79–1.24)	0.85 (0.57–1.26)	1.0	1.04 (0.83–1.31)	0.98 (0.69–1.41)
M versus U2	1.0	0.89 (0.56–1.41)	0.43 (0.13–1.49)	1.0	1.20 (0.78–1.86)	0.84 (0.36–2.00)	1.0	1.02 (0.65–1.62)	1.50 (0.78–2.88)
p16
M/ U/ control	86/254/847	41/126/458	10/19/62	53/164/607	57/162/546	12/32/139	59/169/586	50/172/565	23/40/155
M versus controls1	1.0	0.92 (0.63–1.36)	1.76 (0.57–3.56)	1.0	1.04 (0.73–1.50)	0.87 (0.46–1.65)	1.0	0.89 (0.61–1.30)	1.47 (0.89–2.43)
U versus controls1	1.0	1.00 (0.78–1.27)	0.76 (0.87–3.56)	1.0	1.04 (0.82–1.31)	0.81 (0.53–1.22)	1.0	1.10 (0.88–1.39)	0.93 (0.61–1.36)
M versus U2	1.0	0.90 (0.59–1.38)	1.55 (0.69–3.50)	1.0	0.97 (0.65–1.45)	1.08 (0.53–2.22)	1.0	0.82 (0.54–1.26)	1.61 (0.89–2.89)
RAR-β2
M/ U/ control	93/247/847	44/123/458	9/20/62	54/163/607	72/147/546	9/35/139	68/160/586	62/160/565	11/52/155
M versus controls 1	1.0	0.92 (0.64–1.33)	1.46 (0.70–3.03)	1.0	1.35 (0.94–1.91)	0.67 (0.33–1.37)	1.0	0.96 (0.68–1.37)	0.61 (0.43–0.88)
U versus controls1	1.0	1.00 (0.79–1.27)	1.25 (0.74–2.11)	1.0	0.93 (0.74–1.18)	0.88 (0.59–1.31)	1.0	1.08 (0.85–1.38)	1.27 (0.66–2.45)
M versus U 2	1.0	0.90 (0.60–1.37)	1.20 (0.52–2.75)	1.0	1.45 (0.98–2.13)	0.68 (0.30–1.54)	1.0	0.87 (0.58–1.29)	0.48 (0.24–0.97)

¹Odds ratios and 95% confidence intervals adjusted for age and race.

²Odds ratios and 95% confidence intervals also adjusted for estrogen receptor status.